Conversely, the CEMIP, HSPB1, and PANX2 genes, which interfere with the process of ferroptosis, can effectively promote the survival of prostate cancer cells, suggesting that ferroptosis-related genes may be prognostic biomarkers and potential drug targets for patients with prostate cancer [11–13]. This evidence concerns the gene HSPB1 and prostate cancer.